Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: Correlation with the prognostic factors

Archives of Pathology and Laboratory Medicine

Volumn 124, Issue 5, 2000, Pages 687-693

  Kim, Young Sik ^a,b   Kim, Kwang Hee ^a   Choi, Jung Ah ^a   Lee Han, Ju ^a   Kim, Han Kyeom ^a   Won, Nam Hee ^a   Kim, Insun ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MEMBRANE PROTEIN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SIZE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PROGNOSIS;

ADULT; AGED; ANTIGENS, CD95; CARCINOMA, RENAL CELL; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY GLOMERULUS; KIDNEY NEOPLASMS; KIDNEY TUBULES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEPHRONS; PROGNOSIS; TUMOR ESCAPE; UROTHELIUM;

EID: 12944314964     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Nagata S. Fas and Fas ligand: death factor and its receptor. Adv Immunol. 1994;57:129-144.
2. Krammer PH, Dhein J, Walczak H, et al. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 1994;142:175-191.
3. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
4. Nagata S. Fas ligand and immune evasion. Nat Med. 1996;2:1306-1307.
5. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630-632.
6. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
7. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med. 1996;2:1361-1366.
8. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/Cd95)-ligand-implications for tumor immune escape. Science. 1996;274: 1363-1366.
9. Nichans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997;57:1007-1012.
10. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest. 1997;99:1173-1178.
11. Gratas C, Tohma Y, Van Meir EG, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997;7:863-869.
12. O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas-counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075-1082.
13. Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A. 1997;94: 6420-6425.
14. Gratas C, Tohma Y, Barnas C, et al. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 1998;58:2057-2062.
15. Leithäuser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69: 415-429.
16. Luc X, Elisabeth D, Jacques H, et al. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Clin Pathol Clin Mol Pathol. 1997;50:87-91.
17. Nonomura N, Miki T, Yokoyama M, et al. Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochem Biophys Res Commun. 1996;229:945-951.
18. Horie S, Kano M, Higashihara E, et al. Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol. 1997;27:384-388.
19. Miyake H, Hara I, Gohji K, et al. p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int J Oncol. 1998;12:469-473.
20. Cardi G, Heaney JA, Schned AR, et al. Expression of Fas (APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patient with renal cell carcinoma. Cancer Res. 1998;58:2078-2080.
21. Störkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma. Cancer. 1997;80:987-989.